? d s
Set Items Description
S1 9384424 S CANCER OR TUMOR OR TUMOUR OR MALIGNAN?
S2 3910277 S ANTIBOD?
S3 1034 S HM124 OR HM1(1N)24 OR BST2 OR BST(1N)2
S4 4985 S AU=KAWAI
S5 1179 S AU=MIHARA
S6 25 S AU=KOISHIHARA
S7 162 S S2(3N)S3
S8 119 RD (unique items)
S9 95 S S8 AND S1
S10 95 RD (unique items)
S11 4 S S4 AND S3
S12 1 S S5 AND S3
S13 15 S S6 AND S3
S14 17 S S11 OR S12 OR S13
S15 17 RD (unique items)
S16 1 S S15 NOT S10

? show files

[File 5] **Biosis Previews(R)** 1926-2007/Jul W1

**File 5: BIOSIS has been enhanced with archival data. Please see HELP NEWS 5 for information.*

[File 34] **SciSearch(R) Cited Ref Sci** 1990-2007/Jul W2

[File 35] **Dissertation Abs Online** 1861-2007/Jun

[File 45] **EMCare** 2007/Jun W4

[File 65] **Inside Conferences** 1993-2007/Jul 03

[File 71] **ELSEVIER BIOBASE** 1994-2007/Jul W1

[File 73] **EMBASE** 1974-2007/Jun 26

[File 91] **MANTIS(TM)** 1880-2007/Apr

[File 98] **General Sci Abs** 1984-2007/Jun

[File 144] **Pascal** 1973-2007/Jun W4

[File 149] **TGG Health&Wellness DB(SM)** 1976-2007/Jun W4

[File 155] **MEDLINE(R)** 1950-2007/Jun 29

[File 156] **ToxFile** 1965-2007/Jun W4

[File 159] **Cancerlit** 1975-2002/Oct

**File 159: Cancerlit is no longer updating. Please see HELP NEWS159.*

[File 162] **Global Health** 1983-2007/May

[File 164] **Allied & Complementary Medicine** 1984-2007/Jun

[File 172] **EMBASE Alert** 2007/Jun 26

[File 369] **New Scientist** 1994-2007/Jul W1

[File 370] **Science** 1996-1999/Jul W3

**File 370: This file is closed (no updates). Use File 47 for more current information.*

[File 399] **CA SEARCH(R)** 1967-2007/UD=14702

**File 399: Use is subject to the terms of your user/customer agreement. IPCR/8 classification codes now searchable as IC=. See HELP NEWSIPCR.*

[File 434] **SciSearch(R) Cited Ref Sci** 1974-1989/Dec

[File 444] **New England Journal of Med.** 1985-2007/Jun W4

[File 467] **ExtraMED(tm)** 2000/Dec

[File 654] **US PAT.FULL.** 1976-2007/JUN 28

**File 654: IPCR/8 classification codes now searchable in 2006 records. For information about IC= index changes, see HELP NEWSIPCR.*

<!--StartFragment-->RESULT 11
ABB50295
ID   ABB50295 standard; protein; 180 AA.
XX
AC   ABB50295;
XX
DT   08-FEB-2002 (first entry)
XX
DE   Bone marrow stromal antigen (BST-2) ovarian tumour marker protein, #80.
XX
KW   Ovarian tumour marker gene; human; overexpression; upregulation;
KW   epithelial tumour; cancer; diagnosis; prognosis; disease monitoring;
KW   identification; serous cystadenoma; borderline serous tumour;
KW   serous cystadenocarcinoma; mucinous cystadenocarcinoma;
KW   mucinous cystadenoma; borderline mucinous tumour; endometrioid carcinoma;
KW   undifferentiated carcinoma; clear cell adenocarcinoma; cystadenofibroma;
KW   adenofibroma; Brenner tumour; serial analysis of gene expression; SAGE;
KW   immune response pathway; cell proliferation regulation; protein folding;
KW   membrane localised; secreted; therapeutic target; cytostatic;
KW   gene therapy; vaccine.
XX
OS   Homo sapiens.
XX
PN   WO200175177-A2.
XX
PD   11-OCT-2001.
XX
PF   03-APR-2001; 2001WO-US010947.
XX
PR   03-APR-2000; 2000US-0194336P.
XX
PA   (USSH) US DEPT HEALTH & HUMAN SERVICES.
XX
PI   Morin PJ, Sherman-Baust CA, Pizer ES, Hough CD;
XX
DR   WPI; 2001-626450/72.
DR   N-PSDB; ABA83121.
XX
PT   Detecting and identifying ovarian tumor, identifying increased risk for
PT   developing ovarian cancer, and determining effectiveness of ovarian
PT   cancer treatment, by measuring expression level of ovarian tumor marker
PT   gene.
XX
PS   Claim 23; Page 124; 140pp; English.
XX
CC   The invention relates to methods for diagnosing and prognosing ovarian
CC   tumours in an individual via the detection and measurement of the
CC   expression of ovarian tumour marker genes (ABA83081-ABA83122, ABA83180,
CC   ABA83182 and ABA83184) or segments thereof (ABA83123-ABA83169, ABA83179,
CC   ABA83181 and ABA83183). The methods of the invention are useful for
CC   detecting an ovarian tumour in a patient, for identifying an individual
CC   at increased risk for developing ovarian cancer, in prognostic tests for
CC   assessing the relative severity of ovarian cancer, in tests for
CC   monitoring a patient in remission from ovarian cancer and in tests for
CC   monitoring disease status in a patient being treated for ovarian cancer.
CC   The methods can additionally be used to identify a particular tumour as
CC   being an ovarian tumour (i.e., an epithelial ovarian tumour selected from
CC   serous cystadenoma, borderline serous tumour, serous cystadenocarcinoma,
CC   mucinous cystadenoma, borderline mucinous tumour, mucinous
CC   cystadenocarcinoma, endometrioid carcinoma, undifferentiated carcinoma,
CC   clear cell adenocarcinoma, cystadenofibroma, adenofibroma and Brenner

CC tumour. The ovarian tumour marker genes of the invention were identified
CC using SAGE (serial analysis of gene expression) and were found to be
CC overexpressed in a broad variety of ovarian epithelial tumour cells
CC relative to normal ovarian epithelial cells. The marker genes are
CC implicated in immune response pathways, in the regulation of cell
CC proliferation and in protein folding, and many of these are membrane-
CC localised or secreted. In addition to their use as diagnostic and
CC prognostic markers, the ovarian tumour marker genes or their encoded
CC proteins may be used as therapeutic targets for the treatment and
CC prevention of ovarian cancer. Sequences ABB50257-ABB50299 represent
CC proteins encoded by ovarian tumour marker genes of the invention
XX
SQ Sequence 180 AA;

Query Match 100.0%; Score 889; DB 4; Length 180;
Best Local Similarity 100.0%; Pred. No. 2.2e-77;
Matches 180; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MASTSYDYCRVPMEDGDKRCKLLLGIGILVLLIIVILGVPLIIFTIKANSEACRDGLRAV 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MASTSYDYCRVPMEDGDKRCKLLLGIGILVLLIIVILGVPLIIFTIKANSEACRDGLRAV 60

Qy         61 MECRNVTHLLQQELTEAQKGFQDVEAQAATCNHTVMALMASLDAEKAQGQKKVEELEGEI 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 MECRNVTHLLQQELTEAQKGFQDVEAQAATCNHTVMALMASLDAEKAQGQKKVEELEGEI 120

Qy        121 TTLNHKLQDASAEVERLRRENQVLSVRIADKKYYPSSQDSSSAAAPQLLIVLLGLSALLQ 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 TTLNHKLQDASAEVERLRRENQVLSVRIADKKYYPSSQDSSSAAAPQLLIVLLGLSALLQ 180
```

<!--EndFragment-->